drugset
drugset / Trial / NCT05701995

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

NCT05701995 ↗

Phase 4 Completed 180 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

Timeline

Start
2023-01-31
Primary completion
2024-08-23
Completion
2025-05-29

Outcome

Met primary endpoint

registry NUMBER Deucravacitinib: Full Analysis Set: 33.3 (25.0 to 42.5) Percentage of Participants NCT05701995 ↗

registry analysis (superiority test); Deucravacitinib vs Placebo; p = 0.0001; Odds Ratio (OR) 7.7 (95% CI 2.5 to 23.6); NCT05701995 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule — —

Indications

psoriasis